We developed a radiologic-risk signature (RRS) that serves as a surrogate for the pathologic status of prostate cancer (PCA) and investigated its ability to predict disease-free survival.
This study included 631 patients with localized PCA who underwent prostatic multiparametric MRI before prostatectomy. Images from 426 training datasets were structurally interpreted and correlated to a postoperative Memorial Sloan Kettering Cancer Center (MSKCC) score by a stepwise partial least-squares regression analysis. The developed RRS, compared with a preoperative Kattan nomogram, was validated in a cohort of 205 patients with 3-year follow-up data after prostatectomy in terms of calibration, discrimination, and clinical usefulness. Statistical tests were performed by AUC analysis, Kaplan-Meier test, and decision curve analysis.
The RRS, which consists of 12 preoperative variables, faithfully represented postoperative MSKCC score in 426 training (r = 0.75; p < 0.001) and 205 validation (r = 0.79; p < 0.001) datasets. For patients in the validation group, RRS showed better discriminative power (C-index, 0.859; 95% CI, 0.779-0.939; p = 0.013) than did the preoperative Kattan nomogram (C-index, 0.780; 95% CI, 0.701-0.859) for predicting 3-year biochemical recurrence and showed higher net benefits for a probability threshold of greater than 10%.
Characteristics of RRS can faithfully represent the tumor pathologic status and predict accurately the disease postoperative outcome before prostatectomy.
AJR. American journal of roentgenology. 2018 Jul 11 [Epub ahead of print]
Liang Qi, Chen-Jiang Wu, Jing Zhang, Mei-Ling Bao, Xu Yan, Yu-Dong Zhang
1 Department of Radiology, First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Rd, Nanjing, Jiangsu Province 210009, China., 2 Department of Pathology, First Affiliated Hospital, Nanjing Medical University, Nanjing, China., 3 MR Collaboration NE Asia, Siemens Healthcare, Shanghai, China.